| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | ADARx Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $352.5M | Series C | 8/9/2023 | $200M | $848.26M | $9.75 | Bain Capital Life Sciences, TCGX, Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital, Ascenta Capital, Lilly Asia Ventures, OrbiMed Advisors, SR One Capital Management | ||||
 | Synchron | Healthcare Medical Devices | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $318.41M | Series D | 11/6/2025 | $200M | $821.5M | $36.70 | Double Point Ventures, ARCH Venture Partners, Khosla Ventures, Bezos Expeditions, NeuroTechnology Investors, METIS, National Reconstruction Fund Corporation, T.Rx Capital, QIA, K5 Global, Protocol Labs, IQT | ||||
 | Iambic Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $395.29M | Series B-4 | 4/1/2026 | $32.77M | $671.11M | $3.26 | Undisclosed Investors | ||||
 | Terray Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $326.97M | Series C | 9/9/2026 | $125M | $722.36M | $10.28 | Undisclosed Investors | ||||
 | HistoSonics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $308.72M | Series D-1 | 8/15/2024 | $102.7M | $598.27M | $1.60 | Alpha Wave Ventures, Amzak Health, HealthQuest Capital, Johnson & Johnson Innovation, Venture Investors, Lumira Ventures, Yonjin Venture, State of Wisconsin Investment Board | ||||
 | Rad AI | Healthcare Healthcare Software | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $100.00K | -- | 1 | Not available | -- | -- | $163.36M | Series C | 5/20/2025 | $80.9M | $527.53M | $22.51 | Transformation Capital, Khosla Ventures, World Innovation Lab, UP2398, Kickstart, OCV Partners, Cone Health, Advocate Health, Memorial Hermann Health System, Corewell Health, Atlantic Health System | ||||
 | Verse Medical | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.43M | Series C | 6/10/2025 | $53M | $735.18M | $32.37 | General Catalyst, SignalFire, Sapphire Ventures | ||||
 | City Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.91M | Series B | 6/8/2026 | $99.5M | $571.5M | $14.63 | Viking Global, Sofinnova Investments, Casdin Capital, NYBC Ventures, ARCH Venture Partners, Fidelity, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures | ||||
 | Loyal | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $236.56M | Series C | 2/11/2026 | $95.46M | $614.38M | $12.26 | Age 1, Baillie Gifford | ||||
 | Parabilis Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $811.88M | Series F | 1/8/2026 | $305.25M | $681.2M | $6.16 | RA Capital Management, Fidelity, Janus Henderson Investors, Frazier Life Sciences, Soleus Capital, venBio Partners, Cormorant Asset Management, Nextech Invest, ARCH Venture Partners, Milky Way Investments, GV, T. Rowe Price, Marshall Wace, General Catalyst, Invus, Farallon Capital Management, Foresite Capital, Rock Springs Capital, HBM Healthcare Investments, Samsara BioCapital, Catalio Capital Management, Sixty Degree Capital, Alderline Group | ||||
 | Huma | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $137.16M | Series D-1 | 4/4/2024 | $20.25M | $731.49M | $22.88 | Bayer, Touchstone Investment, Ireon Ventures, Minamour Investments | ||||
 | K Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $465M | Series G-1 | 6/5/2026 | $17.1M | $814.34M | $9.82 | Undisclosed Investors | ||||
 | AliveCor | Healthcare Medical Devices | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $277.15M | Series F | 8/16/2022 | $150M | $943.68M | $14.72 | GE Healthcare, NGK-NTK, Khosla Ventures, Bold Capital Partners, Qualcomm Ventures, WP Global Partners | ||||
 | Cleerly | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $386.48M | Series C | 12/4/2024 | $330.08M | $729.01M | $11.78 | T. Rowe Price Associates, Fidelity Management, Sands Capital, Piper Sandler, Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, Novartis, Pura Vida Investments, Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures, DigiTx Partners, Insight Partners, Battery Ventures | ||||
 | Delfi Diagnostics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $326.47M | Series B | 7/18/2022 | $225M | $685.11M | $4.85 | DFJ Growth, Eli Lilly and Company, Point72, Brown Advisory, Point Field Partners, Initiate Ventures, Open Field Capital, PTX Capital, Cowen Healthcare Investments, Foresite Capital, Menlo Ventures, OrbiMed, T. Rowe Price Associates, Northpond Ventures, Samsara BioCapital, Rock Springs Capital, AV8 Ventures, Illumina Ventures, Osage University Partners, Windham Venture Partners | ||||
 | Endeavor BioMedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $295.58M | Series C | 4/24/2024 | $132.58M | $676.04M | $6.52 | AyurMaya, Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, Woodline Partners, Abrdn Inc, Ally Bridge Group, Avidity Partners, Eckuity Capital, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, T. Rowe Price Associates | ||||
 | Odyssey Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $413.6M | Series D | 9/10/2025 | $213.63M | $527.3M | $14.62 | Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG, Wedbush Healthcare Partners | ||||
 | Cellanome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $307.18M | Series C | 12/22/2025 | $90.84M | $712.61M | $8.49 | Undisclosed Investors | ||||
 | Click Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $167.96M | Series D-1 | 4/9/2026 | $25M | $567.95M | $6.55 | Boehringer Ingelheim | ||||
 | Prompt | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $213.08M | Series B | 9/27/2024 | $206M | $929.95M | $248.60 | Undisclosed Investors | ||||
 | Rakuten Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $874.92M | Series F-3 | 1/7/2026 | $3.6M | $636.9M | $1.03 | Taiwania Capital, Axil Capital Group, Daiwa Securities, Mitsui Sumitomo Insurance Company, Sumitomo Mitsui Banking, ABIES Capital, Nexus CVC, OEP Group, SBI Group, Rakuten, Mickey Mikitani | ||||
 | Cohere Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $196.1M | Series C | 5/14/2025 | $90M | $724.92M | $13.71 | Temasek, Deerfield Management, Define Ventures, Flare Capital Partners, Longitude Capital, Polaris Partners | ||||
 | Collate | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125.5M | Series A | 6/3/2026 | $95M | $724.46M | $43.78 | Redpoint, First Round Capital, Conviction Partners, Y Combinator | ||||
 | Soufflé Therapeutics | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $330.79M | Series B | 7/21/2026 | $134.76M | $506.77M | $2.70 | Undisclosed Investors | ||||